Phagocytosis by human monocytes is required for the secretion of presepsin

Journal of Infection and Chemotherapy

Volumn 21, Issue 8, 2015, Pages 564-569

  Arai, Yasuyuki ^a   Mizugishi, Kiyomi ^a   Nonomura, Kazuhiko ^b   Naitoh, Katsuki ^b   Takaori Kondo, Akifumi ^a   Yamashita, Kouhei ^a  

^a KYOTO UNIVERSITY   (Japan)

^b MOCHIDA PHARMACEUTICAL CO   (Japan)

Author keywords

Hematopoietic cell transplantation; Hemophagocytic syndrome; Monocyte; Phagocytosis; Presepsin; Sepsis

Indexed keywords

BIOLOGICAL MARKER; ELASTASE; LYMPHOCYTE ANTIGEN; PRESEPSIN; UNCLASSIFIED DRUG; URATE; CD14 ANTIGEN; PANCREATIC ELASTASE; PEPTIDE FRAGMENT; PRESEPSIN PROTEIN, HUMAN;

ACUTE LYMPHOBLASTIC LEUKEMIA; ACUTE MYELOBLASTIC LEUKEMIA; ADOLESCENT; ADULT; AGED; ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION; APLASTIC ANEMIA; ARTICLE; BACTEREMIA; CONTROLLED STUDY; ENZYME LINKED IMMUNOSORBENT ASSAY; ESCHERICHIA COLI; FEMALE; GRAFT VERSUS HOST REACTION; HEMOPHAGOCYTIC SYNDROME; HUMAN; HUMAN CELL; IMMUNOSUPPRESSIVE TREATMENT; IN VITRO STUDY; MAJOR CLINICAL STUDY; MALE; MONOCYTE; MULTIPLE MYELOMA; MYELODYSPLASTIC SYNDROME; NEUTROPHIL; NONHODGKIN LYMPHOMA; OVERALL SURVIVAL; PHAGOCYTOSIS; PHAGOSOME; PROGNOSIS; PROTEIN CLEAVAGE; PROTEIN SECRETION; SEPSIS; STAPHYLOCOCCUS EPIDERMIDIS; T CELL LEUKEMIA; ADVERSE EFFECTS; ALLOTRANSPLANTATION; BLOOD; CELL CULTURE; HEMATOPOIETIC STEM CELL TRANSPLANTATION; METABOLISM; MIDDLE AGED; PHYSIOLOGY; SECRETION (PROCESS); YOUNG ADULT;

ADOLESCENT; ADULT; AGED; ANTIGENS, CD14; BACTEREMIA; BIOMARKERS; CELLS, CULTURED; ESCHERICHIA COLI; FEMALE; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMANS; LYMPHOHISTIOCYTOSIS, HEMOPHAGOCYTIC; MALE; MIDDLE AGED; MONOCYTES; NEUTROPHILS; PANCREATIC ELASTASE; PEPTIDE FRAGMENTS; PHAGOCYTOSIS; STAPHYLOCOCCUS EPIDERMIDIS; TRANSPLANTATION, HOMOLOGOUS; YOUNG ADULT;

EID: 84937640315     PISSN: 1341321X     EISSN: 14377780     Source Type: Journal    
DOI: 10.1016/j.jiac.2015.04.011     Document Type: Article

References (30)

1. Shirakawa K., Naitou K., Hirose J., Takahashi T., Furusako S. Presepsin (sCD14-ST): development and evaluation of one-step ELISA with a new standard that is similar to the form of presepsin in septic patients. Clin Chem Lab Med 2011, 49:937-939.
2. Yaegashi Y., Shirakawa K., Sato N., Suzuki Y., Kojika M., Imai S., et al. Evaluation of a newly identified soluble CD14 subtype as a marker for sepsis. JInfect Chemother 2005, 11:234-238.
3. Shozushima T., Takahashi G., Matsumoto N., Kojika M., Okamura Y., Endo S. Usefulness of presepsin (sCD14-ST) measurements as a marker for the diagnosis and severity of sepsis that satisfied diagnostic criteria of systemic inflammatory response syndrome. JInfect Chemother 2011, 17:764-769.
4. Endo S., Suzuki Y., Takahashi G., Shozushima T., Ishikura H., Murai A., et al. Usefulness of presepsin in the diagnosis of sepsis in a multicenter prospective study. JInfect Chemother 2012, 18:891-897.
5. Ulla M., Pizzolato E., Lucchiari M., Loiacono M., Soardo F., Forno D., et al. Diagnostic and prognostic value of presepsin in the management of sepsis in the emergency department: a multicenter prospective study. Crit Care 2013, 17:R168.
6. Cakir Madenci O., Yakupoglu S., Benzonana N., Yucel N., Akbaba D., Orcun Kaptanagasi A. Evaluation of soluble CD14 subtype (presepsin) in burn sepsis. Burns 2014, 40:664-669.
7. Endo S., Suzuki Y., Takahashi G., Shozushima T., Ishikura H., Murai A., et al. Presepsin as a powerful monitoring tool for the prognosis and treatment of sepsis: a multicenter prospective study. JInfect Chemother 2014, 20:30-34.
8. Masson S., Caironi P., Spanuth E., Thomae R., Panigada M., Sangiorgi G., et al. Presepsin (soluble CD14 subtype) and procalcitonin levels for mortality prediction in sepsis: data from the Albumin Italian Outcome Sepsis trial. Crit Care 2014, 18:R6.
9. Masson S., Caironi P., Fanizza C., Thomae R., Bernasconi R., Noto A., et al. Circulating presepsin (soluble CD14 subtype) as a marker of host response in patients with severe sepsis or septic shock: data from the multicenter, randomized ALBIOS trial. Intensive Care Med 2015, 41:12-20.
10. Shirakawa K., Naitou K., Hirose J., Nakamura M., Takeuchi T., Hosaka Y., et al. The new sepsis marker, sCD14-ST, induction mechanism in the rabbit sepsis models. Crit Care 2010, 14:P19.
11. Hiemenz J.W. Management of infections complicating allogeneic hematopoietic stem cell transplantation. Semin Hematol 2009, 46:289-312.
12. Arai Y., Nishinaka Y., Arai T., Morita M., Mizugishi K., Adachi S., et al. Uric acid induces NADPH oxidase-independent neutrophil extracellular trap formation. Biochem Biophys Res Commun 2014, 443:556-561.
13. Arai Y., Yamashita K., Mizugishi K., Watanabe T., Sakamoto S., Kitano T., et al. Serum neutrophil extracellular trap levels predict thrombotic microangiopathy after allogeneic stem cell transplantation. Biol Blood Marrow Transpl 2013, 19:1683-1689.
14. Jordan M.B., Allen C.E., Weitzman S., Filipovich A.H., McClain K.L. How I treat hemophagocytic lymphohistiocytosis. Blood 2011, 118:4041-4052.
15. Przepiorka D., Weisdorf D., Martin P., Klingemann H.G., Beatty P., Hows J., et al. 1994 consensus conference on acute GVHD grading. Bone Marrow Transpl 1995, 15:825-828.
16. Boeckh M., Gooley T.A., Myerson D., Cunningham T., Schoch G., Bowden R.A. Cytomegalovirus pp65 antigenemia-guided early treatment with ganciclovir versus ganciclovir at engraftment after allogeneic marrow transplantation: a randomized double-blind study. Blood 1996, 88:4063-4071.
17. Fine J.P., Gray R.J. Aproportional hazards model for the subdistribution of a competing risk. JAm Stat Assoc 1999, 94:496-509.
18. Martinon F., Petrilli V., Mayor A., Tardivel A., Tschopp J. Gout-associated uric acid crystals activate the NALP3 inflammasome. Nature 2006, 440:237-241.
19. Carlier M.F., Criquet P., Pantaloni D., Korn E.D. Interaction of cytochalasin D with actin filaments in the presence of ADP and ATP. JBiol Chem 1986, 261:2041-2050.
20. Flannagan R.S., Cosio G., Grinstein S. Antimicrobial mechanisms of phagocytes and bacterial evasion strategies. Nat Rev Microbiol 2009, 7:355-366.
21. Saw S., Kale S.L., Arora N. Serine protease inhibitor attenuates ovalbumin induced inflammation in mouse model of allergic airway disease. PLoS ONE 2012, 7:e41107.
22. Henriksen P.A. The potential of neutrophil elastase inhibitors as anti-inflammatory therapies. Curr Opin Hematol 2014, 21:23-28.
23. Sandhaus R.A., Turino G. Neutrophil elastase-mediated lung disease. COPD 2013, 10:60-63.
24. Imahashi N., Inamoto Y., Ito M., Koyama D., Goto T., Onodera K., et al. Clinical significance of hemophagocytosis in BM clot sections during the peri-engraftment period following allogeneic hematopoietic SCT. Bone Marrow Transpl 2012, 47:387-394.
25. Bianchi M.E. DAMPs, PAMPs and alarmins: all we need to know about danger. JLeukoc Biol 2007, 81:1-5.
26. Mussap M., Noto A., Fravega M., Fanos V. Soluble CD14 subtype presepsin (sCD14-ST) and lipopolysaccharide binding protein (LBP) in neonatal sepsis: new clinical and analytical perspectives for two old biomarkers. JMatern Fetal Neonatal Med 2011, 24:12-14.
27. Arai Y., Yamashita K., Mizugishi K., Takaori-Kondo A., Chiba T., Watanabe T. The implications of myelodysplastic syndrome - associated chromosomal abnormalities in the development of graft-versus-host disease. Eur J Haematol 2013, 90:525-530.
28. Bas S., Gauthier B.R., Spenato U., Stingelin S., Gabay C. CD14 is an acute-phase protein. JImmunol 2004, 172:4470-4479.
29. Bazil V., Strominger J.L. Shedding as a mechanism of down-modulation of CD14 on stimulated human monocytes. JImmunol 1991, 147:1567-1574.
30. Preis M., Lowrey C.H. Laboratory tests for paroxysmal nocturnal hemoglobinuria. Am J Hematol 2014, 89:339-341.